

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2022 (SECOND) Regular Session
VOTING RECORD

Bill No. 169-36 (LS) As amended by the Committee on Committee on Health, Land, Justice, and Culture.	Speaker Antonio R. Unpingco Legislative Session Hall Guam Congress Building April 1, 2022					
NAME	Aye	Nay	Not Voting/ Abstained	Out During Roll Call	Absent	Excused
Senator V. Anthony Ada	✓					
Senator Frank Blas Jr.	✓					
Senator Joanne Brown	✓					
Senator Christopher M. Dueñas	✓					
Senator James C. Moylan	✓					
Vice Speaker Tina Rose Muña Barnes	✓					
Senator Telena Cruz Nelson					✓	✓
Senator Sabina Flores Perez	✓					
Senator Clynton E. Ridgell					✓	✓
Senator Joe S. San Agustin	✓					
Senator Amanda L. Shelton	✓					
Senator Telo T. Taitague	✓					
Senator Jose "Pedo" Terlaje	✓					
Speaker Therese M. Terlaje	✓					
Senator Mary Camacho Torres					✓	✓

TOTAL

12

0

**Not
Voting/
Abstained**

**Out
During
Roll Call**

3

Absent


3

Excused

Aye

Nay

CERTIFIED TRUE AND CORRECT:



 RENNAE V. C. MENO
 Clerk of the Legislature

I = Pass

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2021 (FIRST) Regular Session

Bill No. 169-36 (LS)

As amended by the Committee on Health,
Land, Justice, and Culture.

*

Introduced by:

Telena Cruz Nelson

**AN ACT TO *AMEND* APPENDIX A, APPENDIX B,
APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF
CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED,
RELATIVE TO UPDATING THE LIST OF SCHEDULED
CONTROLLED SUBSTANCES PROVIDED IN THE
GUAM UNIFORM CONTROLLED SUBSTANCES ACT.**

BE IT ENACTED BY THE PEOPLE OF GUAM:

Section 1. Legislative Findings and Intent. *I Liheslaturan Guåhan* finds that the continued health and public safety of the people of Guam necessitates a unified legal framework that regulates the use, dispensation, and categorization of controlled substances. The purpose of this Act is to update Schedule I through Schedule V of controlled substances based on their medical utility and potential for dependence or abuse.

I Liheslaturan Guåhan further finds that the Department of Public Health and Social Services (DPHSS) has the authority to administer this Act and to add, delete, or otherwise update Appendices A, B, C, D, and E in accordance with § 67.201 of Chapter 67, Title 9, Guam Code Annotated. The following updated lists of controlled substances are in accordance with DPHSS's findings and research.

1 It is, therefore, the intent of *I Liheslaturan Guåhan* and DPHSS to properly
2 update the list of scheduled drugs to reflect federal regulations provided in §1308.11,
3 §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, U.S. Code of Federal
4 Regulations, relative to schedules of controlled substances.

5 **Section 2.** APPENDIX A of Chapter 67, Title 9, Guam Code Annotated, is
6 hereby *amended* to read:

7 “(a) Opiates. Any of the following opiates, including their isomers,
8 esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
9 existence of such isomers, esters, ethers and salts is possible within the
10 specific chemical designation (for purposes of 3-methylthiofentanyl only, the
11 term isomer includes the optical and geometric isomers):

12 (1) acetyl-alpha-methylfentanyl (*N*-[1-(1-methyl-2-
13 phenethyl)-4-piperidinyl]-*N*-phenylacetamide);

14 (2) acetylmethadol;

15 (3) acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
16 phenylacetamide);

17 (4) acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
18 phenylacrylamide; also known as: acryloylfentanyl);

19 (5) AH-7921 (3,4-dichloro-*N*-[(1-dimethylamino)
20 cyclohexylmethyl]benzamide);

21 (6) allylprodine;

22 (7) alphacetylmethadol (except levoalphacetylmethadol also
23 known as levo-alpha-acetylmethadol, levomethadyl acetate, or
24 LAAM);

25 (8) alphameprodine;

26 (9) alphamethadol;

- 1 (10) alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
2 ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
3 propanilido) piperidine);
- 4 (11) alpha-methylthiofentanyl (N-[1-methyl-2-(2-
5 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 6 (12) benzethidine;
- 7 (13) betacetylmethadol;
- 8 (14) beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
9 piperidinyl]-N-phenylpropamide);
- 10 (15) beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
11 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
- 12 (16) *beta*-Hydroxythiofentanyl N-[1-[2-hydroxy-2-(thiophen-
13 2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide ;
- 14 (17) betameprodine;
- 15 (18) betamethadol;
- 16 (19) betaprodine;
- 17 (20) butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
18 phenylbutyramide);
- 19 (21) clonitazene;
- 20 (22) cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
21 phenylcyclopropanecarboxamide);
- 22 (23) dextromoramide;
- 23 (24) diampromide;
- 24 (25) diethylthiambutene;
- 25 (26) difenoxin;
- 26 (27) dimenoxadol;
- 27 (28) dimepheptanol;

- 1 (29) dimethylthiambutene;
2 (30) dioxaphetyl butyrate;
3 (31) dipipanone;
4 (32) ethylmethylthiambutene;
5 (33) etonitazene;
6 (34) etoxeridine;
7 (35) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
8 phenethylpiperidin-4-yl)isobutyramide; also known as: *para*-
9 fluoroisobutyryl fentanyl);
10 (36) furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
11 phenylfuran-2-carboxamide);
12 (37) furethidine;
13 (38) hydroxypethidine;
14 (39) ketobemidone;
15 (40) levomoramide;
16 (41) levophenacymorphan;
17 (42) methoxyacetyl fentanyl (2-methoxy-*N*-(1-
18 phenethylpiperidin-4-yl)-*N*-phenylacetamide);
19 (43) 3-methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-
20 piperidyl]-*N*-phenylpropanamide);
21 (44) 3-methylthiofentanyl (*N*-[3-methyl-1-(2- thienylethyl)-4-
22 piperidinyl]-*N*-phenylpropanamide);
23 (45) morpheridine;
24 (46) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
25 (47) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine);
26 (48) noracymethadol;
27 (49) norlevorphanol;

- 1 (50) normethadone;
- 2 (51) norpipanone;
- 3 (52) ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-
4 phenethylpiperidin-4-yl)acetamide);
- 5 (53) *ortho*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-
6 phenethylpiperidin-4-yl)propionamide); also known as: 2-
7 fluorofentanyl;
- 8 (54) *para*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
9 phenethylpiperidin-4-yl)butyramide);
- 10 (55) *para*-fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-
11 phenethyl)-4-piperidinyl] propanamide);
- 12 (56) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 13 (57) phenadoxone;
- 14 (58) phenampromide;
- 15 (59) phenomorphan;
- 16 (60) phenoperidine;
- 17 (61) piritramide;
- 18 (62) proheptazine;
- 19 (63) properidine;
- 20 (64) propiram;
- 21 (65) racemoramide;
- 22 (66) tetrahydrofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-
23 yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
- 24 (67) thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-
25 piperidinyl]-propanamide);
- 26 (68) tilidine;
- 27 (69) trimeperidine; and

1 (70) U-47700(3,4-Dichloro-N-[2-
2 (dimethylamino)cyclohexyl]-N-methylbenzamide).

3 (b) Opium derivatives. Any of the following opium derivatives, its
4 salts, isomers and salts of isomers whenever the existence of such salts,
5 isomers, and salts of isomers is possible within the specific chemical
6 designation:

- 7 (1) acetorphine;
- 8 (2) acetyldihydrocodeine;
- 9 (3) benzylmorphine;
- 10 (4) codeine methylbromide;
- 11 (5) codeine-N-Oxide;
- 12 (6) cyprenorphine;
- 13 (7) desomorphine;
- 14 (8) dihydromorphine;
- 15 (9) drotebanol;
- 16 (10) etorphine (except hydrochloride salt);
- 17 (11) heroin;
- 18 (12) hydromorphenol;
- 19 (13) methyldesorphine;
- 20 (14) methyldihydromorphine;
- 21 (15) morphine methylbromide;
- 22 (16) morphine methylsulfonate;
- 23 (17) morphine-N-oxide;
- 24 (18) myrophine;
- 25 (19) nicocodeine;
- 26 (20) nicomorphine;
- 27 (21) normorphine;

1 (22) pholcodine; and

2 (23) thebacon.

3 (c) Hallucinogenic substances. Any material, compound, mixture, or
4 preparation which contains any quantity of the following hallucinogenic
5 substances, or which contains any of its salts, isomers, and salts of isomers
6 whenever the existence of such salts, isomers, and salts of isomers is possible
7 within the specific chemical designation (for purposes of this paragraph only,
8 the term “isomer” includes the optical, position and geometric isomers):

9 (1) Alpha-ethyltryptamine (some trade or other names:
10 etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-
11 aminobutyl) indole; α -ET; and AET);

12 (2) 4-bromo-2,5-dimethoxy-amphetamine (some trade or
13 other names: 4-bromo-2,5-dimethoxy- α -methylphenethylamine;
14 4-bromo-2,5-DMA);

15 (3) 4-Bromo-2,5-dimethoxyphenethylamine (some trade or
16 other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-
17 desmethyl DOB; 2C-B, Nexus);

18 (4) 2,5-dimethoxyamphetamine (some trade or other names:
19 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA);

20 (5) 2,5-dimethoxy-4-ethylamphet-amine (some trade or other
21 name: DOET);

22 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other
23 name: 2C-T-7);

24 (7) 4-methoxyamphetamine (some trade or other names: 4-
25 methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA);

26 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;

1 (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or
2 other names: 4-methyl-2,5-dimethoxy- α -methylphenethylamine;
3 “DOM”; and “STP”);

4 (10) 3,4-methylenedioxy amphetamine;

5 (11) 3,4-methylenedioxymethamphetamine (MDMA);

6 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
7 as: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-
8 ethyl MDA, MDE, MDEA);

9 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
10 known as: N-hydroxy-alpha-methyl-3,4(methylenedioxy)-
11 phenethylamine, and N-hydroxy MDA);

12 (14) 3,4,5-trimethoxy amphetamine;

13 (15) 5-methoxy-N,N-dimethyltryptamine (some trade or other
14 names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT;

15 (16) Alpha-methyltryptamine (other name: AMT);

16 (17) bufotenine (some trade or other names: 3-(β -
17 Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-
18 indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
19 mappine);

20 (18) diethyltryptamine (some trade or other names: N,N-
21 Diethyltryptamine; DET);

22 (19) dimethyltryptamine (some trade or other name: DMT);

23 (20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-
24 MeO-DIPT);

1 (21) ibogaine (some trade or other names: 7-Ethyl-
2 6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
3 [1',2':1,2] azepino [5,4-b] indole; Tabernanthe iboga);

4 (22) lysergic acid diethylamide;

5 (23) [Repealed];

6 (24) mescaline;

7 (25) parahexyl-7374(some trade or other names: 3-Hexyl-1-
8 hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
9 Synhexyl);

10 (26) peyote (meaning all parts of the plant presently classified
11 botanically as *Lophophora williamsii* Lemaire, whether growing or not,
12 the seeds thereof, any extract from any part of such plant, and every
13 compound, manufacture, salts, derivative, mixture, or preparation of
14 such plant, its seeds or extracts);

15 (27) N-ethyl-3-piperidyl benzilate;

16 (28) N-methyl-3-piperidyl benzilate;

17 (29) psilocybin;

18 (30) psilocyn;

19 (31) [Repealed];

20 (32) ethylamine analog of phencyclidine (some trade or other
21 names:N-ethyl-1-phenylcyclohexylamine,(1-phenylcyclohexyl)
22 ethylamine,N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE);

23 (33) pyrrolidine analog of phencyclidine (some trade or other
24 names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);

25 (34) thiophene analog of phencyclidine (some trade or other
26 names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of
27 phencyclidine, TPCP, TCP);

- 1 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (some other
2 names: TCPy)
- 3 (36) 4-methylmethcathinone (Mephedrone);
- 4 (37) 3,4-methylenedioxypropylvalerone (MDPV);
- 5 (38) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E);
- 6 (39) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D);
- 7 (40) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);
- 8 (41) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);
- 9 (42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-
10 T-2);
- 11 (43) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine
12 (2C-T-4);
- 13 (44) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H);
- 14 (45) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
- 15 (46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-
16 P);
- 17 (47) 3,4-Methylenedioxy-N-methylcathinone (Methylone);
- 18 (48) (1-pentyl-1*H*-indol-3-yl) (2,2,3,3-
19 tetramethylcyclopropyl) methanone (UR-144);
- 20 (49) [1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-
21 tetramethylcyclopropyl) methanone (5-fluoro-UR-144, XLR11);
- 22 (50) *N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide
23 (APINACA, AKB48);
- 24 (51) quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22;
25 QUPIC);
- 26 (52) quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate
27 (5-fluoro-PB-22; 5F-PB-22);

- 1 (53) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
2 fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA);
- 3 (54) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
4 indazole-3-carboxamide (ADB-PINACA);
- 5 (55) 2-(4-iodo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
6 ethanamine (25I-NBOMe, 2C-I-NBOMe);
- 7 (56) 2-(4-chloro-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
8 ethanamine (25C-NBOMe, 2C-C-NBOMe);
- 9 (57) 2-(4-bromo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
10 ethanamine (25B-NBOMe, 2C-B-NBOMe);
- 11 (58) 4-methyl-*N*-ethylcathinone (4-MEC);
- 12 (59) 4-methyl-*alpha*-pyrrolidinopropiophenone(4-MePPP);
- 13 (60) *alpha*-pyrrolidinopentiophenone (α -PVP);
- 14 (61) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
15 (butylone, bk-MBDB);
- 16 (62) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 17 (63) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
18 (pentylone, bk-MBDB);
- 19 (64) 4-fluoro-*N*-methylcathinone (4-FMC; flephedrone);
- 20 (65) 3-fluoro-*N*-methylcathinone (3-FMC);
- 21 (66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one
22 (naphyrone);
- 23 (67) *alpha*-pyrrolidinobutiophenone (α -PBP);
- 24 (68) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
25 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA);
- 26 (69) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
27 indazole-3-carboxamide (AB-PINACA);

1 (70) [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-
2 yl)methanone (THJ-2201);

3 (71) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
4 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-
5 CHMINACA; ADB- CHMINACA);

6 (72) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
7 carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-
8 MDMB-PINACA);

9 (73) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
10 carboxamido)-3-methylbutanoate (Other names: 5F-AMB);

11 (74) *N*-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-
12 carboxamide (Other names: 5F-APINACA, 5F-AKB48);

13 (75) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
14 fluorobenzyl)-1*H*-indazole-3-carboxamide (Other names: ADB-
15 FUBINACA);

16 (76) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
17 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
18 CHMICA, MMB-CHMINACA);

19 (77) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
20 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
21 FUBINACA); and

22 (78) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
23 carboxamido)-3-methylbutanoate, (FUB-AMB, MMB-FUBINACA,
24 AMB-FUBINACA).

25 (d) Depressants. Any material, compound, mixture or preparation
26 which contains any quantity of the following substances having a depressant
27 effect on the central nervous system, including its salts, isomers and salts of

1 isomers whenever the existence of such salts, isomers, and salts of isomers is
2 possible within the specific chemical designation:

3 (1) gamma-hydroxybutyric acid (some other names include
4 GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-
5 hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

6 (2) mecloqualone; and

7 (3) methaqualone.

8 (e) *Stimulants*. Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances having a stimulant
10 effect on the central nervous system, including its salts, isomers and salts of
11 isomers:

12 (1) Aminorex (other names: aminoxaphen; 2-amino-5-
13 phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine);

14 (2) N-Benzylpiperazine (other names: BZP, 1-
15 benzylpiperazine);

16 (3) Cathinone (other names: 2-amino-1-phenyl-1-
17 propanone; alpha-aminopropiophenone; 2-aminopropiophenone; and
18 norephedrone);

19 (4) Fenethylamine;

20 (5) Methcathinone (other names: 2-(methylamino)-
21 propiophenone; alpha-(methylamino)propiophenone; 2-
22 (methylamino)-1-phenylpropan-1-one; alpha-*N*-
23 methylaminopropiophenone; monomethylpropion; ephedrone; *N*-
24 methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and
25 UR1432), its salts, optical isomers and salts of optical isomers);

26 (6) (\pm)*cis*-4-methylaminorex (other name: (\pm)*cis*-4,5-
27 dihydro-4-methyl-5-phenyl-2-oxazolamine);

1 (7) N-ethylamphetamine; and

2 (8) *N,N*-dimethylamphetamine (also known as *N,N*-alpha-
3 trimethyl-benzeneethanamine; *N,N*-alpha-trimethylphenethylamine).

4 (f) *Cannabimimetic agents*. Any material, compound, mixture or
5 preparation which contains any quantity of the following substances or which
6 contains their salts, isomers, and salts of isomers whenever the existence of
7 such salts, isomers, and salts of isomers is possible within the specific
8 chemical designation:

9 (1) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
10 hydroxycyclohexyl]-phenol CP-47,497);

11 (2) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
12 phenol, (cannabicyclohexanol or CP-47,497 C8-homolog);

13 (3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and
14 geometric isomers, salts and salts of isomers (other names: JWH-073);

15 (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole, its
16 optical, positional, and geometric isomers, salts and salts of isomers
17 (other names: JWH-200);

18 (5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and
19 geometric isomers, salts and salts of isomers (other names: JWH-018
20 and AM678);

21 (6) *Salvia divinorum* or *Salvinorum A*; all parts of the plant
22 presently classified botanically as *Salvia divinorum*, whether growing
23 or not, the seeds thereof, any extract from any part of such plant, and
24 every compound, manufacture, salts, derivative, mixture, or
25 preparation of such plant, its seeds or extracts;

26 (7) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

27 (8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

- 1 (9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
2 (10) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
3 (11) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
4 (12) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
5 (13) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
6 (14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and
7 RCS-4);
8 (15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole
9 7008(SR-18 and RCS-8);
10 (16) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); and
11 (17) any synthetic cannabinoid.

12 (g) Temporary listing of substances subject to emergency
13 scheduling. Any material, compound, mixture or preparation which contains
14 any quantity of the following substances:

- 15 (1) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide, its
16 isomers, esters, ethers, salts and salts of isomers, esters and ethers (other
17 name: valeryl fentanyl);
18 (2) *N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-
19 yl)butyramide, its isomers, esters, ethers, salts and salts of isomers,
20 esters and ethers (other name: *para*-methoxybutyryl fentanyl);
21 (3) *N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-
22 yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers,
23 esters and ethers (other name: *para*-chloroisobutyryl fentanyl);
24 (4) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide,
25 its isomers, esters, ethers, salts and salts of isomers, esters and ethers
26 (other name: isobutyryl fentanyl);

1 (5) *N*-(1-phenethylpiperidin-4-yl)-*N*-
2 phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and
3 salts of isomers, esters and ethers (other name: cyclopentyl fentanyl);

4 (6) Naphthalen-1-yl 1-(5-fluoropentyl)-1*H*-indole-3-
5 carboxylate, its optical, positional, and geometric isomers, salts and
6 salts of isomers (other names: NM2201; CBL2201);

7 (7) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
8 fluoropentyl)-1*H*-indazole-3-carboxamide, its optical, positional, and
9 geometric isomers, salts and salts of isomers (other names: 5F-AB-
10 PINACA);

11 (8) 1-(4-cyanobutyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-
12 3-carboximide, its optical, positional, and geometric isomers, salts and
13 salts of isomers (other names: 4-CN-CUMYL-BUTINACA; 4-cyano-
14 CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-
15 BINACA; SGT-78);

16 (9) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
17 carboxamido)-3-methylbutanoate, its optical, positional, and
18 geometric isomers, salts and salts of isomers (other names: MMB-
19 CHMICA, AMB- CHMICA);

20 (10) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
21 pyrrolo[2,3-*b*]pyridine-3-carboxamide, its optical, positional, and
22 geometric isomers, salts and salts of isomers (other names: 5F-
23 CUMYL- P7AICA);

24 (11) *N*-Ethylpentylone, its optical, positional, and geometric
25 isomers, salts and salts of isomers (other names: ephylone, 1-(1,3-
26 benzodioxol-5-yl)- 2-(ethylamino)-pentan-1-one);

1 (12) ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-
2 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
3 salts and salts of isomers (trivial name: 5F-EDMB-PINACA);

4 (13) methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-
5 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
6 salts and salts of isomers (trivial name: 5F-MDMB-PICA);

7 (14) *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-
8 carboxamide, its optical, positional, and geometric isomers, salts and
9 salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48
10 *N*-(4-FLUOROBENZYL));

11 (15) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
12 indazole-3-carboxamide, its optical, positional, and geometric isomers,
13 salts and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-
14 25);

15 (16) (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-
16 tetramethylcyclopropyl) methanone, its optical, positional, and
17 geometric isomers, salts and salts of isomers (trivial name: FUB-144);

18 (17) *N*-Ethylhexedrone, its optical, positional, and geometric
19 isomers, salts and salts of isomers (Other name: 2-(ethylamino)-1-
20 phenylhexan-1-one);

21 (18) *alpha*-Pyrrolidinohexanophenone, its optical, positional,
22 and geometric isomers, salts and salts of isomers (Other names: α -PHP;
23 *alpha*-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidine-1-yl)hexan-
24 1-one);

25 (19) 4-Methyl-*alpha*-ethylaminopentiophenone, its optical,
26 positional, and geometric isomers, salts and salts of isomers (Other
27 names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

1 (20) 4-Methyl-*alpha*-pyrrolidinohexiophenone, its
2 optical, positional, and geometric isomers, salts and salts of
3 isomers (Other names: MPHP; 4-methyl-*alpha*-
4 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidine-1-
5 yl)hexan-1-one);

6 (21) *alpha*-Pyrrolidinoheptaphenone, its optical, positional,
7 and geometric isomers, salts and salts of isomers (Other names: PV8;
8 1-phenyl-2-(pyrrolidine-1-yl)heptan-1-one); and

9 (22) 4'-Chloro-*alpha*-pyrrolidinovalerophenone, its optical,
10 positional, and geometric isomers, salts and salts of isomers (Other
11 names: 4-chloro- α -PVP; 4'-chloro-*alpha*-pyrrolidinopentiophenone; 1-
12 (4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-one).”

13 **Section 3.** APPENDIX B of Chapter 67, Title 9, Guam Code Annotated, is
14 hereby *amended* to read:

15 “(a) Substances, vegetable origin or chemical synthesis. Any of the
16 following substances whether produced directly or indirectly by extraction
17 from substances of vegetable origin, or independently by means of chemical
18 synthesis, or by a combination of extraction and chemical synthesis:

19 (1) Opium and opiate, and any salt, compound, derivative, or
20 preparation of opium or opiate excluding apomorphine, thebaine-
21 derived butorphanol, dextrophan, nalbuphine, naldemedine,
22 nalmefene, naloxegol, naloxone, 6 β -naltrexol and naltrexone, and their
23 respective salts, but including the following:

- 24 (A) codeine;
25 (B) dihydroetorphine;
26 (C) ethylmorphine;
27 (D) etorphine hydrochloride;

- 1 (E) granulated opium;
- 2 (F) hydrocodone;
- 3 (G) hydromorphone;
- 4 (H) metopon;
- 5 (I) morphine;
- 6 (J) noroxymorphone;
- 7 (K) opium extracts;
- 8 (L) opium fluid;
- 9 (M) oripavine;
- 10 (N) oxycodone;
- 11 (O) oxymorphone;
- 12 (P) powdered opium;
- 13 (Q) raw opium;
- 14 (R) thebaine; and
- 15 (S) tincture of opium.

16 (2) Any salt, compound, derivative, or preparation thereof
17 which is chemically equivalent or identical with any of the substances
18 listed in Subsection (a)(1) of this Section, except that these substances
19 shall not include the isoquinoline alkaloids of opium;

20 (3) Opium poppy and poppy straw;

21 (4) Coca leaves and any salt, compound, derivative, or
22 preparation of coca leaves, (including cocaine and ecgonine and their
23 salts, isomers, derivatives, and salts of isomers and derivatives), and
24 any salt, compound, derivative, or preparation thereof which is
25 chemically equivalent or identical with any of these substances, except
26 that the substances shall not include:

1 (A) decocainized coca leaves or extraction of coca
2 leaves, which extractions do not contain cocaine or ecgonine; or

3 (B) ioflupane.

4 (5) Concentrate of poppy straw (the crude extract of poppy
5 straw in either liquid, solid, or powder form which contains the
6 phenanthrene alkaloids of the opium poppy).

7 (b) Opiates. Any of the following opiates, including its isomers,
8 esters, ethers, salts, and salts of isomers, esters, and ethers whenever the
9 existence of such isomers, esters, ethers, and salts is possible within the
10 specific chemical designation, dextrorphan and levopropoxyphene excepted:

11 (1) alfentanil;

12 (2) alphaprodine;

13 (3) anileridine;

14 (4) bezitramide;

15 (5) bulk dextropropoxyphene (non-dosage forms);

16 (6) carfentanil;

17 (7) dihydrocodeine;

18 (8) diphenoxylate;

19 (9) fentanyl;

20 (10) isomethadone;

21 (11) levo-alphaacetylmethadol [some other names: levo-alpha-
22 acetylmethadol, levomethadyl acetate, LAAM];

23 (12) levomethorphan;

24 (13) levorphanol;

25 (14) metazocine;

26 (15) methadone;

1 (16) methadone-intermediate, 4-cyano-2-dimethylamino-4,4-
2 diphenyl butane;

3 (17) moramide-intermediate, 2-methyl-3-morpholino-1, 1-
4 diphenylpropane-carboxylic acid;

5 (18) pethidine (meperidine);

6 (19) pethidine-intermediate-A, 4-cyano-1-methyl-4-
7 phenylpiperidine;

8 (20) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-
9 carboxylate;

10 (21) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-
11 4-carboxylic acid;

12 (22) phenazocine;

13 (23) piminodine;

14 (24) racemethorphan;

15 (25) racemorphan;

16 (26) remifentanil;

17 (27) sufentanil;

18 (28) tapentadol; and

19 (29) thiafentanil.

20 (c) Stimulants. Any material, compound, mixture, or preparation
21 which contains any quantity of the following substances having a stimulant
22 effect on the central nervous system:

23 (1) amphetamine, its salts, optical isomers, and salts of its
24 optical isomers;

25 (2) methamphetamine, its salts, isomers, and salts of its
26 isomers;

27 (3) phenmetrazine and its salts;

1 (4) methylphenidate; and

2 (5) lisdexamfetamine, its salts, isomers, and salts of its
3 isomers.

4 (d) Depressants. Any material, compound, mixture, or preparation
5 which contains any quantity of the following substances having a depressant
6 effect on the central nervous system, including its salts, isomers, and salts of
7 isomers whenever the existence of such salts, isomers, and salts of isomers is
8 possible within the specific chemical designation:

9 (1) amobarbital;

10 (2) pentobarbital;

11 (3) phencyclidine;

12 (4) secobarbital; and

13 (5) glutethimide;

14 (e) Hallucinogenic substances.

15 (1) Nabilone (other name for nabilone: (\pm)-trans-3-(1,1-
16 dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-
17 9H-dibenzo[b,d] pyran-9-one).

18 (f) Immediate precursors. Any material, compound, mixture, or
19 preparation containing any quantity of the following substances:

20 (1) Immediate precursor to amphetamine and
21 methamphetamine:

22 (A) phenylacetone (other names: phenyl-2-propanone;
23 P2P; benzyl methyl ketone; methyl benzyl ketone);

24 (2) Immediate precursors to phencyclidine (PCP):

25 (A) 1-phenylcyclohexylamine; and

26 (B) 1-piperidinocyclohexanecarbonitrile (PCC).

27 (3) Immediate precursor to fentanyl:

1 (A) 4-anilino-N-phenethylpiperidine (ANPP).”

2 **Section 4.** APPENDIX C of Chapter 67, Title 9, Guam Code Annotated, is
3 hereby *amended* to read:

4 “(a) Stimulants. Any material, compound, mixture, or preparation
5 which contains any quantity of the following substances having a stimulant
6 effect on the central nervous system, including its salts, isomers (whether
7 optical, positional, or geometric), and salts of such isomers whenever the
8 existence of such salts, isomers, and salts of isomers is possible within the
9 specific chemical designation:

10 (1) Those compounds, mixtures, or preparations in dosage
11 unit form containing any stimulant substance included in Schedule II
12 which compounds, mixtures, or preparations were listed as an
13 excepted compound on August 25, 1971, pursuant to the federal
14 Controlled Substances Act, and any other drug of the quantitative
15 composition shown in that list for those drugs or which is the same
16 except for containing a lesser quantity of controlled substances;

17 (2) benzphetamine;

18 (3) chlorphentermine;

19 (4) clortermine; and

20 (5) phendimetrazine.

21 (b) Depressants. Any material, compound, mixture, or preparation
22 containing any quantity of the following substances having a depressant effect
23 on the central nervous system:

24 (1) any compound, mixture, or preparation containing:

25 (A) amobarbital;

26 (B) secobarbital; and

1 (C) pentobarbital; or any salt thereof and one or more
2 other active medicinal ingredients which are not listed in any
3 schedule.

4 (2) any of the following drugs, or their salts, in suppository
5 dosage form, approved by the Federal Food and Drug Administration
6 for marketing only as a suppository:

7 (A) amobarbital;

8 (B) secobarbital; and

9 (C) pentobarbital.

10 (3) a substance containing any quantity of a derivative of
11 barbituric acid or any salt of a derivative of barbituric acid;

12 (4) chlorhexadol;

13 (5) embutramide;

14 (6) any drug product containing gamma hydroxybutyric acid,
15 including its salts, isomers, and salts of isomers, for which an
16 application is approved under Section 505 of the Federal Food, Drug,
17 and Cosmetic Act;

18 (7) ketamine, its salts, isomers, and salts of isomers (other
19 names: (\pm) -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);

20 (8) lysergic acid;

21 (9) lysergic acid amide;

22 (10) methyprylon;

23 (11) perampanel, and its salts, isomers and salts of isomers.

24 (12) sulfondiethylmethane;

25 (13) sulfonethylmethane;

26 (14) sulfonmethane;

1 (15) tiletamine and zolazepam, or any salt thereof (Some trade
2 or other names for a tiletamine-zolazepam combination product:
3 Telazol; (Some trade or other names for tiletamine: 2-(ethylamino)-2-
4 (2-thienyl)-cyclohexanone. Some trade or other names for zolazepam:
5 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-*e*] [1,4]-
6 diazepin-7(1*H*)-one, flupyrzapon);

7 (c) Nalorphine.

8 (d) Narcotic Drugs.

9 (1) Any material, compound, mixture, or preparation
10 containing any of the following narcotic drugs, or their salts calculated
11 as the free anhydrous base or alkaloid, in limited quantities as set forth
12 below:

13 (A) not more than 1.8 grams of codeine per 100
14 milliliters or not more than 90 milligrams per dosage unit, with
15 an equal or greater quantity of an isoquinoline alkaloid of opium;

16 (B) not more than 1.8 grams of codeine per 100
17 milliliters or not more than 90 milligrams per dosage unit, with
18 one or more active, nonnarcotic ingredients in recognized
19 therapeutic amounts;

20 (C) not more than 300 milligrams of dihydrocodeine
21 (hydrocodone) per 100 milliliters or not more than 15 milligrams
22 per dosage unit, with one or more active-nonnarcotic ingredients
23 in recognized therapeutic amounts;

24 (D) not more than 1.8 grams of Dihydrocodeine
25 (hydrocodone) per 100 milliliters or not more than 90 milligrams
26 per dosage unit, with one or more active-nonnarcotic ingredients
27 in recognized therapeutic amounts;

1 (E) not more than 300 milligrams of ethylmorphine per
2 100 milliliters or not more than 15 milligrams per dosage unit,
3 with one or more active, nonnarcotic ingredients in recognized
4 therapeutic amounts;

5 (F) not more than 500 milligrams of opium per 100
6 milliliters or per 100 grams, or not more than 25 milligrams per
7 dosage unit, with one or more active, nonnarcotic ingredients in
8 recognized therapeutic amounts;

9 (G) not more than 50 milligrams of morphine per 100
10 milliliters or per 100 grams with one or more active,
11 nonnarcotic ingredients in recognized therapeutic amounts; and

12 (H) not more than 50 milligrams of morphine per 100
13 milliliters or per 100 grams with one or more active, nonnarcotic
14 ingredients in recognized therapeutic amounts.

15 (2) Any material, compound, mixture, or preparation
16 containing any of the following narcotic drugs or their salts as set below:

17 (A) buprenorphine;

18 (e) Anabolic Steroids. Any drug or hormonal substance chemically
19 and pharmacologically related to testosterone (other than estrogens,
20 progestins, corticosteroids, and dehydroepiandrosterone), and includes:

21 (1) $3\beta,17$ -dihydroxy-5 α -androstane;

22 (2) $3\alpha,17\beta$ -dihydroxy-5 α -androstane;

23 (3) 5α -androstan-3,17-dione;

24 (4) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androst-1-ene);

25 (5) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy-5 α -androst-1-ene);

26 (6) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene;

- 1 (7) 5-androstenediol ($\beta,17\beta$ -dihydroxy-androst-5-ene);
- 2 (8) 1-androstenedione ($[5\alpha]$ -androst-1-en-3,17- dione);
- 3 (9) 4-androstenedione (androst-4-en-3,17-dione);
- 4 (10) 5-androstenedione (androst-5-en-3,17-dione);
- 5 (11) bolasterone ($7\alpha,17\alpha$ - dimethyl- 17β -hydroxyandrost-4-
- 6 en-3-one);
- 7 (12) boldenone (17β -hydroxyandrost-1,4- diene-3-one);
- 8 (13) boldione (androsta-1,4-diene-3,17-dione);
- 9 (14) calusterone ($7\beta,17\alpha$ -dimethyl- β -hydroxyandrost-4-en-3-
- 10 one);
- 11 (15) clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
- 12 (16) dehydrochloromethyltestosterone (4-chloro- 17β -
- 13 hydroxy- 17α -methyl- androst-1,4-dien-3-one);
- 14 (17) desoxymethyltestosterone (17α -methyl- 5α -androst-2-en-
- 15 17β -ol) (Also known as, “madadol”);
- 16 (18) $\Delta 1$ -dihydrotestosterone (Also known as, “1-
- 17 testosterone”) (17β - hydroxy- 5α -androst-1-en-3-one);
- 18 (19) 4-dihydrotestosterone (17β -hydroxy-androstan-3-one);
- 19 (20) drostanolone (17β -hydroxy- 2α -methyl- 5α -androstan-3-
- 20 one);
- 21 (21) ethylestrenol (17α -ethyl- 17β -hydroxyestr-4-ene);
- 22 (22) fluoxymesterone (9-fluoro- 17α -methyl- $11\beta,17\beta$ -
- 23 dihydroxyandrost- 4-en-3-one);
- 24 (23) formebolone (2-formyl- 17α -methyl- $11\alpha,17\beta$ -
- 25 dihydroxyandrost-1,4-dien-3-one);

- 1 (24) furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-
2 furazan);
- 3 (25) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 4 (26) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-
5 one);
- 6 (27) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-
7 en-3-one);
- 8 (28) mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-
9 one);
- 10 (29) mesterolone (1 α methyl-17 β -hydroxy-[5 α]-androstan-3-
11 one);
- 12 (30) methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-
13 dien-3-one);
- 14 (31) methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-
15 ene);
- 16 (32) methasterone (2 α ,17 α -dimethyl-5 α -androstan-17 β -ol-3-
17 one);
- 18 (33) methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-
19 one);
- 20 (34) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstan-3-one;
- 21 (35) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstan-3-one;
- 22 (36) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 23 (37) 17 α -methyl-4-hydroxynandrolone(17 α -methyl- 4-
24 hydroxy-17 β -hydroxyestr-4-en-3-one);
- 25 (38) methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-
26 dien-3-one);

- 1 (39) methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-
2 trien-3-one);
- 3 (40) methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-
4 en-3-one);
- 5 (41) mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-
6 one);
- 7 (42) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy- 17 α -
8 methyl-5 α -androst-1-en-3- one) (Also known as, “17- α -methyl-1-
9 testosterone”);
- 10 (43) nandrolone (17 β -hydroxyestr-4-en-3-one);
- 11 (44) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 12 (45) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 13 (46) 19-nor-5-androstenediol (3 β , 17 β -dihydroxyestr-5-ene);
- 14 (47) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 15 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-
16 3,17-dione);
- 17 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 18 (50) 19-nor-5-androstenedione(estr-5-en-3,17-dione);
- 19 (51) norbolethone (13 β , 17 α -diethyl-17 β - hydroxygon-4-en-
20 3-one);
- 21 (52) norclostebol (4-chloro-17 β - hydroxyestr-4-en-3-one);
- 22 (53) norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-
23 one);
- 24 (54) normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-
25 one);

- 1 (55) oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-
2 androstan-3-one);
- 3 (56) oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-
4 en-3-one);
- 5 (57) oxymetholone (17 α -methyl-2-hydroxymethylene-17 β -
6 hydroxy- [5 α]-androstan-3-one);
- 7 (58) prostanazol (17 β -hydroxy-5 α androstan[3,2-c]pyrazole);
- 8 (59) stanozolol (17 α -methyl-17 β -hydroxy-[5 α -androst-2-
9 eno[3,2-c]-pyrazole);
- 10 (60) stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-
11 one);
- 12 (61) testolactone (13-hydroxy-3-oxo-13,17 secoandrosta-1,4-
13 dien-17-oic acid lactone);
- 14 (62) testosterone (17 β -hydroxyandrost-4-en-3-one);
- 15 (63) tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-
16 4,9,11-trien-3-one);
- 17 (64) trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and
- 18 (65) Any salt, ester, or ether of a drug or substance described
19 or listed in this Subsection (e) of this Section. Except such term does
20 not include an anabolic steroid that is expressly intended for
21 administration through implants to cattle or other nonhuman species
22 and which has been approved by the Secretary of Health and Human
23 Services for such administration. If any person prescribes, dispenses,
24 or distributes such steroid for human use, such person shall be
25 considered to have prescribed, dispensed, or distributed an anabolic
26 steroid within the meaning of this paragraph. DPHSS may exempt by

1 rule a compound, mixture, or preparation containing a stimulant or
2 depressant substance listed in subsections A and B from the application
3 of all or part of this Act, if the compound, mixture, or preparation
4 contains one or more active medicinal ingredients not having a
5 stimulant or depressant effect on the central nervous system and the
6 admixtures are in combinations, quantity, proportion, or concentration
7 that vitiate the potential for abuse of the substances having a stimulant
8 or depressant effect on the central nervous system.

9 (f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil
10 and encapsulated in a soft gelatin capsule in a U.S. Food and Drug
11 Administration approved product (Some other names for dronabinol: (6aR-
12 *trans*)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-ibenzo[*b,d*]pyran-
13 1-ol]).”

14 **Section 5.** APPENDIX D of Chapter 67, Title 9, Guam Code Annotated, is
15 hereby *amended* to read:

16 “(a) Narcotic drugs. Any material, compound, mixture, or preparation
17 containing any of the following narcotic drugs, or their salts calculated as the
18 free anhydrous base or alkaloid, in limited quantities as set forth below:

19 (1) not more than 1 milligram of difenoxin and not less than
20 25 micrograms of atropine sulfate per dosage unit;

21 (2) dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-
22 diphenyl-3-methyl-2-propionoxybutane); and

23 (3) 2-[(dimethylamino)methyl]-1-(3-
24 methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers
25 and salts of these isomers (including tramadol).

26 (b) Depressants. Any material, compound, mixture, or preparation
27 which contains any quantity of the following substances, including any salts,

1 isomers, and salts of isomers whenever the existence of such salts,
2 isomers, and salts of isomers is possible within the specific chemical
3 designation:

- 4 (1) alfaxalone;
- 5 (2) alprazolam;
- 6 (3) barbital;
- 7 (4) brexanolone;
- 8 (5) bromazepam;
- 9 (6) camazepam;
- 10 (7) carisoprodol;
- 11 (8) chloral betaine;
- 12 (9) chloral hydrate;
- 13 (10) chlordiazepoxide;
- 14 (11) clobazam;
- 15 (12) clonazepam;
- 16 (13) clorazepate;
- 17 (14) clotiazepam;
- 18 (15) cloxazolam;
- 19 (16) delorazepam;
- 20 (17) diazepam;
- 21 (18) dichloraphenazone;
- 22 (19) estazolam;
- 23 (20) ethchlorvynol;
- 24 (21) ethinamate;
- 25 (22) ethyl loflazepate;
- 26 (23) fludiazepam;
- 27 (24) flunitrazepam;

- 1 (25) flurazepam;
- 2 (26) fospropofol;
- 3 (27) halazepam;
- 4 (28) haloxazolam;
- 5 (29) ketazolam;
- 6 (30) loprazolam;
- 7 (31) lorazepam;
- 8 (32) lormetazepam;
- 9 (33) mebutamate;
- 10 (34) medazepam;
- 11 (35) meprobamate;
- 12 (36) methohexital;
- 13 (37) methylphenobarbital (mephobarbital);
- 14 (38) midazolam;
- 15 (39) nimetazepam;
- 16 (40) nitrazepam;
- 17 (41) nordiazepam;
- 18 (42) oxazepam;
- 19 (43) oxazolam;
- 20 (44) petrichloral;
- 21 (45) phenobarbital;
- 22 (46) pinazepam;
- 23 (47) prazepam;
- 24 (48) quazepam;
- 25 (49) suvorexant;
- 26 (50) temazepam;
- 27 (51) tetrazepam;

- 1 (52) triazolam;
- 2 (53) zaleplon;
- 3 (54) zolpidem; and
- 4 (55) zopiclone.

5 (c) Fenfluramine. Any material, compound, mixture, or preparation
6 which contains any quantity of the following substances, including its salts,
7 isomers (whether optical, position, or geometric), and salts of such isomers,
8 whenever the existence of such salts, isomers, and salts of isomers is possible:

- 9 (1) fenfluramine.

10 (d) Lorcaserin. Any material, compound, mixture, or preparation
11 which contains any quantity of the following substances, including its salts
12 isomers and salts of such isomers, whenever the existence of such salts,
13 isomers, and salts of isomers is possible:

- 14 (1) lorcaserin.

15 (e) Stimulants. Any material, compound, mixture, or preparation
16 containing any quantity of the following substances having a stimulant effect
17 on the central nervous system, including their salts, isomers, and salts of
18 isomers:

- 19 (1) cathine ((+)-norpseudoephedrine);
- 20 (2) diethylpropion;
- 21 (3) fencamfamin;
- 22 (4) fenproporex;
- 23 (5) mazindol;
- 24 (6) mefenorex;
- 25 (7) modafinil;
- 26 (8) pemoline (including organometallic complexes and
27 chelates thereof);

- 1 (9) phentermine;
2 (10) pipradrol;
3 (11) sibutramine;
4 (12) solriamfetol (2-amino-3-phenylpropyl carbamate;
5 benzenepropanol, beta-amino-carbamate (ester)); and
6 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

7 (f) Other substances. Any material, compound, mixture, or
8 preparation containing any quantity of the following substance, including its
9 salts:

- 10 (1) pentazocine;
11 (2) butorphanol (including its optical isomers); and
12 (3) eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-
13 dimethylphenyl]-1-oxopropyl][(1S)-1-4-phenyl-1H-imidazol-2-
14 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its optical
15 isomers and salts of isomers.

16 (g) DPHSS may exempt by rule any compound, mixture, or
17 preparation containing a depressant substance listed in subsection B from the
18 application of all or part of this Act, if the compound, mixture, or preparation
19 contains one or more active medicinal ingredients not having a depressant
20 effect on the central nervous system and the admixtures are in combinations,
21 quantity, proportion, or concentration that vitiate the potential for abuse of the
22 substances having a depressant effect on the central nervous system.”

23 **Section 6.** APPENDIX E of Chapter 67, Title 9, Guam Code Annotated, is
24 hereby *amended* to read:

25 “(a) Narcotic drugs. Unless specifically excepted or unless listed in
26 another schedule, any material, compound, mixture, or preparation containing
27 any of the following narcotic drugs and their salts, as set forth below:

1 (b) Narcotic drugs containing non-narcotic active medicinal
2 ingredients. Any compound, mixture, or preparation containing any of the
3 following narcotic drugs, or their salts calculated as the free anhydrous base
4 or alkaloid, in limited quantities as set forth below, which shall include one or
5 more non-narcotic active medicinal ingredients in sufficient proportion to
6 confer upon the compound, mixture, or preparation, valuable medicinal
7 qualities other than those possessed by the narcotic drug alone:

8 (1) not more than 200 milligrams of codeine per 100
9 milliliters or per 100 grams;

10 (2) not more than 100 milligrams of dihydrocodeine per 100
11 milliliters or per 100 grams;

12 (3) not more than 100 milligrams of ethylmorphine per 100
13 milliliters or per 100 grams;

14 (4) not more than 2.5 milligrams of diphenoxylate and not less
15 than 25 micrograms of atropine sulfate per dosage unit;

16 (5) not more than 100 milligrams of opium per 100
17 milliliters or per 100 grams; and

18 (6) not more than 0.5 milligram of difenoxin and not less
19 than 25 micrograms of atropine sulfate per dosage unit.

20 (c) Stimulants. Any material, compound, mixture, or preparation
21 containing any quantity of the following substances having a stimulant effect
22 on the central nervous system, including their salts, isomers and salts of
23 isomers:

24 (1) pyrovalerone.

25 (d) Depressants. Any material, compound, mixture, or preparation
26 which contains any quantity of the following substances having a depressant
27 effect on the central nervous system, including its salts:

1 (1) brivaracetam ((S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-
2 yl]butanamide) (also referred to as BRV; UCB-34714; Briviact)
3 including its salts;

4 (2) cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-
5 yl)ethyl]carbamate; 2*H*-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-,
6 carbamate(ester), (alpha*R*)-; carbamic acid (*R*)-(+)-1-(2-
7 chlorophenyl)-2-(2*H*-tetrazol-2-yl)ethyl ester);

8 (3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-
9 phenyl]-carbamic acid ethyl ester];

10 (4) lacosamide [(*R*)-2-acetoamido-*N*-benzyl-3-methoxy-
11 propionamide];

12 (5) lasmiditan [2,4,6-trifluoro-*N*-(6-(1-methylpiperidine-4-
13 carbonyl)pyridine-2-yl)-benzamide]; and

14 (6) pregabalin [(*S*)-3-(aminomethyl)-5-methylhexanoic
15 acid].”

16 **Section 7. Severability.** If any provision of this Act or its application to any
17 person or circumstance is held invalid, the invalidity does not affect other provisions
18 or applications of this Act that can be given effect without the invalid provision or
19 application, and to this end the provisions of this Act are severable.